Search
Abdavomeran
go.drugbank.com/drugs/DB15695Investigational[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a "foldon" trimerization domain derived … BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.
Synonyms: BNT162b1 SARS-CoV-2 VaccineNKG2D-ACE2 CAR-NK Cell
go.drugbank.com/drugs/DB15727InvestigationalThe ACE2 is a receptor for SARS-Cov-2, binding to the S-protein of the viral envelope and competitively inhibiting SARS-Cov-2 infection of type II alveolar epithelial cells. … The GM-CSF acts as a neutralizer for the CAR-T cell-mediated cytokine release and neurotoxicity.
Barnidipine
go.drugbank.com/drugs/DB09227InvestigationalThe active component is composed of a single optical isomer (*3'S, 4S* configuration), which is the most potent and longest-acting of the four enantiomers [A31567]. … after a 1-year and 2-year follow-up period in 91% of the patients who had an initial response to the drug [A7842].
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingRhein
go.drugbank.com/drugs/DB13174ExperimentalRhein is an anthraquinone metabolite of rheinanthrone and senna glycoside is present in many medicinal plants including Rheum palmatum, Cassia tora, Polygonum multiflorum, and Aloe barbadensis [A19247] … It is known to have hepatoprotective, nephroprotective, anti-cancer, anti-inflammatory, and several other protective effects.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsRosuvastatin
go.drugbank.com/drugs/DB01098ApprovedInvestigationalfound in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol. … as well as the need for surgical revascularization or angioplasty following a heart attack.
Mixtures: ROSUVINA LEGRAND® E 10/40, ROSUVINA LEGRAND® E 10/20Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigationalgamma 1 (IgG1). … [A261130] Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa).
Products: EYLIA® SOLUCIÓN PARA INYECCIÓN INTRAVÍTREA, ZALTRAP 100MG/4ML INFUZYONLUK KONSANTRE COZELTI İÇEREN FLAKON, 3 ADETIcosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalIcosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). … It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.
Categories: Fatty Acids, Omega-3Synonyms: E-EPA, (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl esterArbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalArbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.
Categories: GABA-B Receptor AgonistsEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: XTANDI ® 40 MG, XTANDI® 40 MGRaxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. … Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.